MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last?

Most New 2024 Biopharma Offerings Trade Lower Later

 
• By Mandy Jackson

MBX, Zenas and Bicara delivered positive returns in their first days of trading, but that has not always translated to good long-term results for drug developers that launched US IPOs this year.

IPO - acronym from wooden blocks with letters, Initial Public Offering IPO concept
Biopharma IPO gross proceeds total $2.86bn year-to-date • Source: Shutterstock

More from Financing

More from Business